The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
about
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Impaired autophagic flux and its related inflammation in patients with adult-onset Still's disease.Radiation therapy and immunotherapy: what is the optimal timing or sequencing?Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells.
P2860
The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
The TLR7 agonist imiquimod ind ...... ing radiotherapy for melanoma.
@ast
The TLR7 agonist imiquimod ind ...... ing radiotherapy for melanoma.
@en
type
label
The TLR7 agonist imiquimod ind ...... ing radiotherapy for melanoma.
@ast
The TLR7 agonist imiquimod ind ...... ing radiotherapy for melanoma.
@en
prefLabel
The TLR7 agonist imiquimod ind ...... ing radiotherapy for melanoma.
@ast
The TLR7 agonist imiquimod ind ...... ing radiotherapy for melanoma.
@en
P2093
P2860
P356
P1433
P1476
The TLR7 agonist imiquimod ind ...... ing radiotherapy for melanoma.
@en
P2093
Byung-Il Yoon
Hyo-Ji Lee
Hyun-Jeong Ko
Jeong A Han
Jeong Hyun Cho
Jongseon Choe
Kee-Ho Lee
Keun-Cheol Kim
Sun Shim Choi
Tae-Wook Hahn
P2860
P304
24932-24948
P356
10.18632/ONCOTARGET.15326
P407
P577
2017-02-15T00:00:00Z